|
Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The real-time quantitative RT-PCR analysis of the CEA and/or CK20 transcripts in the peritoneal lavage fluid is useful for predicting the peritoneal recurrence in patients who are undergoing a curative resection for gastric cancer.
|
17667927 |
2007 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors.
|
16778108 |
2006 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the expression of miR‑130a in plasma in gastric cancer patients was upregulated and diagnostic value for gastric cancer of miR-130a is more effective than the tumor markers carcinoembryonic antigen (CEA) and CA-199. miR-130a directly targeted runt‑related transcription factor 3 (RUNX3) and promoted gastric cancer tumorigenesis by targeting RUNX3. miR-130a may therefore be a useful marker for the diagnosis and prognosis of gastric cancer.
|
26134263 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative RT-PCR with CEA and CK-20 mRNA as target markers was introduced for peritoneal lavage diagnosis in 141 patients with clinically advanced gastric cancer from 9 different institutes.
|
24155213 |
2014 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a dual-label time-resolved fluoroimmunoassay (TRFIA) to simultaneously detect carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) in human serum to aid the diagnosis and prognosis of gastric cancer.
|
29729233 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aims to evaluate and compare the diagnostic accuracy of 5 common tumor biomarkers (CA19-9, CA125, PG, IncRNA, and DNA methylation) and CEA and their combinations for diagnosing gastric cancer through network meta-analysis method, and to rank these tests using a superiority index.
|
29742692 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between FITC, CEA, NLR, foxp3+ Treg lymphocytes (both 1- and 3-year OS), CA 19-9, or VEGF and GC OS were supported by highly suggestive evidence, however, the results should be interpreted cautiously due to inadequate methodological quality as deemed by AMSTAR 2.0.
|
31850212 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of ADAM 8 and CEA further increased the diagnostic accuracy to predict GC (sensitivity, 81.8%; specificity, 84.0%).
|
31347325 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from receiver operating characteristic (ROC) curve analysis disclosed a better diagnostic accuracy of plasma DEK than carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), and C-reactive protein (CRP), highlighting its potential as an effective plasma biomarker for GC.
|
31766266 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated the prognostic factors in gastric cancer including growth factors and their receptors and intra-peritoneal CEA (1,2).
|
12820444 |
2003 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that CEACAM5 is a promising biomarker for GC prewarning and prognostic evaluation.
|
26374829 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, CEA, CA50 and CA72-4 are commonly used as tumor markers for gastric cancer by immunoassays.
|
30303958 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentrations of serum CEA in gastric cancer were higher than normal controls.
|
12854131 |
2003 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, CEACAM6 may serve as a better marker for predicting OS in GC than CEA.
|
28883649 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, combined use of MPV, PDW and CEA can accurately distinguish gastric cancer from gastric ulcer and controls.
|
28977972 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were significant differences in age, gender, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 153 between gastric cancer and healthy controls (<i>P</i><0.05).
|
31308753 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
sLAG3 in PB was poorly expressed and its expression was positively correlated with IL-12 and IFN-γ expression in GC patients. sLAG3 was proved to have a higher diagnostic value than CEA in GC.
|
30223387 |
2018 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with stage I GC, the sensitivity of serum olfactomedin 4 (25%) and Reg IV (35%) was superior to that of CA19-9 (5%) or CEA (3%).
|
19670418 |
2009 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positive prediction rates of circulating miR-21 in GC stages I to IV were all around 90%, while those of CA199 and CEA were around or less than 50%.
|
26063956 |
2015 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Univariate analysis showed that the factors related to PD in GC were: carbohydrate antigen (CA) 125 (<i>P</i> < 0.0001), CA19-9 (<i>P</i> < 0.0001), CA72-4 (<i>P</i> < 0.0001), FLR (<i>P</i> < 0.0001), neutrophil-to-lymphocyte ratio (NLR) (<i>P</i> < 0.0001), albumin-to- lymphocyte ratio (ALR) (<i>P</i> < 0.0001), platelet-to-lymphocyte ratio (PLR) (<i>P</i> = 0.013), and carcinoembryonic antigen (CEA) (<i>P</i> = 0.031).
|
31750248 |
2019 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 are the most commonly used tumor markers in gastric cancer, the differences in the characteristics of these two markers remain unclear, because most previous studies have included many patients who were positive for both markers.
|
27566604 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of L-3-phosphoserine phosphatase and CEA using real-time RT-PCR improves accuracy in detection of peritoneal micrometastasis of gastric cancer.
|
15154633 |
2004 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the SFs, only HNRNPA1 presented greater than 50 % upregulation (cancer/normal mucosa > 2-fold) incidences and CEA-comparable, acceptable (>70 %) detection accuracy (74 %) for GC.
|
27282379 |
2016 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positive rate for a diagnosis of GC increased from 16.3% to 29.3% when S-p53-Ab was combined with CEA in this study.
|
28373470 |
2017 |
|
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
So far the value of conventional tumour markers such as Ca72-4 or carcinoembryonic antigen is limited, and even markers developed from molecular biological studies on the carcinogenesis of gastric cancer, such as E-cadherin and others, have not proved to be of adequate sensitivity and specificity to allow the early detection of gastric cancer.
|
16825900 |
2006 |